AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
Two clinical readouts delivered in Q1; five more expected by year-end
Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine
First images of alpha-synuclein in patients’ brains presented at AD/PDTM Conference provide clinical proof-of-concept for ACI-12589 as a PET tracer for alpha-synucleinopathies (e.g. MSA)
Strong financial position of CHF 173.8 million ensures the Company is fully financed through at least Q1 2024
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the quarter ended March 31, 2022, and provided a corporate update.